Drug Maker Can’t Shake Antitrust Action over Alleged “Samples Blockade” to Delay Generic Entry
- September 13, 2024
Actelion Pharmaceuticals Ltd and Janssen Research & Development LLC (collectively, Actelion), subsidiaries of Johnson & Johnson, must face an action alleging the refusal to sell samples of their blood pressure medication to generic drug companies for bioequivalence testing violated the antitrust laws, the U.S. District Court for the District of Maryland held September 6.
ARTICLE TAGS
You must be logged in to access this content.